A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review.
Pathol Res Pract
; 259: 155371, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38820929
ABSTRACT
BACKGROUND:
Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with BRAF V600E mutation-positive NSCLC. Nevertheless, the treatment strategy for NSCLC patients with BRAF non-V600E mutations remains limited. CASE PRESENTATION Here, we present a NSCLC patient with a BRAF N581S mutation, which is a class III BRAF mutation, and this patient had a durable response to targeted therapy with combined anlotinib and tislelizumab.CONCLUSION:
We hope to bring more attention to rare non-V600 BRAF mutations by presenting this case of NSCLC.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quinolines
/
Antineoplastic Combined Chemotherapy Protocols
/
Proto-Oncogene Proteins B-raf
/
Antibodies, Monoclonal, Humanized
/
Adenocarcinoma of Lung
/
Indoles
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Pathol Res Pract
Year:
2024
Document type:
Article